Haleon is trading 12.1% down at $8.79 in pre-market after cutting its 2026 organic revenue growth guidance to around 2.5%.

  • The October 29 Q3 update reported 2.6% organic revenue growth and lowered guidance from 3%–5% previously.
  • Haleon cited weaker cough, cold and flu demand and announced a £500 million buyback.